nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

19.06.2021 | Original Article

Head-to-head comparison of ⁶⁸Ga-DOTATATE PET/CT and ¹⁸F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study

verfasst von: Qingxing Liu, Jie Zang, Yingying Yang, Qing Ling, Huanwen Wu, Pengyan Wang, Lin Lu, Zhaohui Zhu

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Localizing the source of ectopic adrenocorticotropic hormone secretion (EAS) is challenging. This study compared the diagnostic value of ⁶⁸Ga-DOTATATE PET/CT and ¹⁸F-FDG PET/CT in tumors with EAS.

Methods

Thirty-six patients with a suspicion of EAS were enrolled to undergo both ⁶⁸Ga-DOTATATE PET/CT and ¹⁸F-FDG PET/CT within 4 weeks for comparison. Twenty-three underwent surgical resection or biopsy. Immunohistochemical staining for SSTR2 and Ki-67 was performed to correlate with ⁶⁸Ga-DOTATATE uptake and ¹⁸F-FDG uptake, respectively.

Results

EAS tumors were observed in 20/23 patients. Among the 20 patients with histologically proven EAS tumors, ⁶⁸Ga-DOTATATE PET/CT correctly identified the tumor in 15 (75.0%), with an SUV_max ranging from 1.4 to 20.7 (6.7 ± 5.5). ¹⁸F-FDG PET/CT correctly identified the tumor in 12 (60.0%) patients, with an SUV_max ranging from 1.8 to 10.0 (4.0 ± 2.1). Moreover, ⁶⁸Ga-DOTATATE PET/CT unmasked the sources of EAS in 6 patients with negative ¹⁸F-FDG uptake, and ¹⁸F-FDG PET/CT unmasked the sources in 3 patients with negative ⁶⁸Ga-DOTATATE uptake, resulting in EAS tumors being identified in 18 (90%) patients by combining ⁶⁸Ga-DOTATATE PET/CT and ¹⁸F-FDG PET/CT.

Conclusions

⁶⁸Ga-DOTATATE PET/CT and ¹⁸F-FDG PET/CT are complementary in localizing and discriminating the source of EAS. ⁶⁸Ga-DOTATATE PET/CT combined with ¹⁸F-FDG PET/CT had higher detection rate than each alone.

Trial registration

⁶⁸Ga-DOTATATE PET/CT in Neuroendocrine Tumors (NCT04041882)

URL of registry

https://clinicaltrials.gov/ct2/show/NCT04041882

Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol. 1994;40:479–84. https://doi.org/10.1111/j.1365-2265.1994.tb02486.x.CrossRef

Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, et al. Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol. 2011;75:436–42. https://doi.org/10.1111/j.1365-2265.2011.04124.x.CrossRef

Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet. 2015;386:913–27. https://doi.org/10.1016/s0140-6736(14)61375-1.CrossRefPubMed

Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet. 2006;367:1605–17. https://doi.org/10.1016/s0140-6736(06)68699-6.CrossRefPubMed

Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BMK, Colao A. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4:611–29. https://doi.org/10.1016/s2213-8587(16)00086-3.CrossRefPubMed

Javanmard P, Duan D, Geer EB. Mortality in patients with endogenous Cushing’s syndrome. Endocrinol Metab Clin N Am. 2018;47:313–33. https://doi.org/10.1016/j.ecl.2018.02.005.CrossRef

Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab. 2005;90:4955–62. https://doi.org/10.1210/jc.2004-2527.CrossRefPubMed

Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454–62. https://doi.org/10.1210/jc.2007-2734.CrossRefPubMedPubMedCentral

Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91:371–7. https://doi.org/10.1210/jc.2005-1542.CrossRefPubMed

10.

Sathyakumar S, Paul TV, Asha HS, Gnanamuthu BR, Paul MJ, Abraham DT, et al. Ectopic Cushing syndrome: a 10-year experience from a tertiary care center in southern India. Endocr Pract. 2017;23:907–14. https://doi.org/10.4158/ep161677.or.CrossRefPubMed

11.

Aniszewski JP, Young WF Jr, Thompson GB, Grant CS, van Heerden JA. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surg. 2001;25:934–40. https://doi.org/10.1007/s00268-001-0032-5.CrossRefPubMed

12.

Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, et al. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion. Cancer. 2011;117:4381–9. https://doi.org/10.1002/cncr.26029.CrossRefPubMed

13.

Wannachalee T, Turcu AF, Bancos I, Habra MA, Avram AM, Chuang HH, et al. The clinical impact of [(68) Ga]-DOTATATE PET/CT for the diagnosis and management of ectopic adrenocorticotropic hormone-secreting tumours. Clin Endocrinol. 2019;91:288–94. https://doi.org/10.1111/cen.14008.CrossRef

14.

Isidori AM, Sbardella E, Zatelli MC, Boschetti M, Vitale G, Colao A, et al. Conventional and nuclear medicine imaging in ectopic Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab. 2015;100:3231–44. https://doi.org/10.1210/JC.2015-1589.CrossRefPubMedPubMedCentral

15.

de Bruin C, Hofland LJ, Nieman LK, van Koetsveld PM, Waaijers AM, Sprij-Mooij DM, et al. Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing’s syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab. 2012;97:455–62. https://doi.org/10.1210/jc.2011-1264.CrossRefPubMed

16.

Pacak K, Ilias I, Chen CC, Carrasquillo JA, Whatley M, Nieman LK. The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing’s syndrome. J Clin Endocrinol Metab. 2004;89:2214–21. https://doi.org/10.1210/jc.2003-031812.CrossRefPubMed

17.

Kakade HR, Kasaliwal R, Jagtap VS, Bukan A, Budyal SR, Khare S, et al. Ectopic ACTH-secreting syndrome: a single-center experience. Endocr Pract. 2013;19:1007–14. https://doi.org/10.4158/EP13171.OR.CrossRefPubMed

18.

Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J. 2010;57:1061–9. https://doi.org/10.1507/endocrj.k10e-265.CrossRefPubMed

19.

Zemskova MS, Gundabolu B, Sinaii N, Chen CC, Carrasquillo JA, Whatley M, et al. Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab. 2010;95:1207–19. https://doi.org/10.1210/jc.2009-2282.CrossRefPubMedPubMedCentral

20.

Moraes AB, Taboada GF, Carneiro MP, Neto LV, Wildemberg LE, Madi K, et al. Utility of [(18)F] fluoro-2-deoxy-D: -glucose positron emission tomography in the localization of ectopic ACTH-secreting tumors. Pituitary. 2009;12:380–3. https://doi.org/10.1007/s11102-008-0125-3.CrossRefPubMed

21.

Xu H, Zhang M, Zhai G, Zhang M, Ning G, Li B. The role of integrated (18)F-FDG PET/CT in identification of ectopic ACTH secretion tumors. Endocrine. 2009;36:385–91. https://doi.org/10.1007/s12020-009-9247-2.CrossRefPubMed

22.

Kumar J, Spring M, Carroll PV, Barrington SF, Powrie JK. 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol. 2006;64:371–4. https://doi.org/10.1111/j.1365-2265.2006.02471.x.CrossRef

23.

Karageorgiadis AS, Papadakis GZ, Biro J, Keil MF, Lyssikatos C, Quezado MM, et al. Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing Cushing syndrome: a diagnostic dilemma and how to solve it. J Clin Endocrinol Metab. 2015;100:141–8. https://doi.org/10.1210/jc.2014-2945.CrossRefPubMed

24.

Varlamov E, Hinojosa-Amaya JM, Stack M, Fleseriu M. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience. Pituitary. 2019;22:445–55. https://doi.org/10.1007/s11102-019-00972-w.CrossRefPubMed

25.

Santhanam P, Taieb D, Giovanella L, Treglia G. PET imaging in ectopic Cushing syndrome: a systematic review. Endocrine. 2015;50:297–305. https://doi.org/10.1007/s12020-015-0689-4.CrossRefPubMed

26.

Ozkan ZG, Kuyumcu S, Balkose D, Ozkan B, Aksakal N, Yilmaz E, et al. The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing ectopic ACTH producing tumors. Mol Imaging Radionucl Ther. 2013;22:49–55. https://doi.org/10.4274/Mirt.69775.CrossRefPubMedPubMedCentral

27.

Gilardi L, Colandrea M, Fracassi SL, Sansovini M, Paganelli G. (68) Ga- DOTA(0) -Tyr(3) octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours. Clin Endocrinol. 2014;81:152–3. https://doi.org/10.1111/cen.12313.CrossRef

28.

Venkitaraman B, Karunanithi S, Kumar A, Bal C, Ammini AC, Kumar R. (6)(8)Ga-DOTATOC PET-CT in the localization of source of ectopic ACTH in patients with ectopic ACTH-dependent Cushing’s syndrome. Clin Imaging. 2014;38:208–11. https://doi.org/10.1016/j.clinimag.2013.10.007.CrossRefPubMed

Titel: Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study
verfasst von: Qingxing Liu
Jie Zang
Yingying Yang
Qing Ling
Huanwen Wu
Pengyan Wang
Lin Lu
Zhaohui Zhu
Publikationsdatum: 19.06.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2021
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05370-8

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Head-to-head comparison of ⁶⁸Ga-DOTATATE PET/CT and ¹⁸F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study

Abstract

Purpose

Methods

Results

Conclusions

Trial registration

URL of registry

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Trial registration

URL of registry

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2021

Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function

Magnetic resonance fingerprinting: an overview

Integrating artificial intelligence into radiology practice: undergraduate students’ perspective

Let’s embrace optical imaging: a growing branch on the clinical molecular imaging tree

Both [68Ga]Ga-FAPI and [18F]FDG PET/CT missed bone metastasis in a patient with breast cancer

New technologies—the best is yet to come